Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Richard Holt

Orthopaedic Surgery of the Spine Louisville, KY Medical Doctor

NPI 1669455630 CMS profile 347571

250 E Liberty St, Suite 202, Louisville, KY 40202

Open in the dashboard

General payments

$2,703

42 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Richard Holt of Louisville, KY is reported in the CMS Open Payments database as having received $2,703 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $13 1
2023 General $14 1
2022 General $267 8
2021 General $216 13
2020 General $174 11
2019 General $2,018 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Holt
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Richard Holt were reported at $0. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Richard Holt Orthopaedic Surgery of the Spine median Middle half National median
2019 $2,018 $2,106 $337–$18,608 $163
2020 $174 $1,213 $156–$15,082 $114
2021 $216 $1,834 $271–$15,617 $132
2022 $267 $2,015 $320–$17,036 $149
2023 $14 $1,925 $336–$14,599 $160
2024 $13 $2,110 $341–$12,483 $164
2025 $0 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. NuVasive, Inc. $1,554 1 payment
  2. Teva Pharmaceuticals USA, Inc. $294 4 payments
  3. Spineology Inc. $197 1 payment
  4. UCB, Inc. $153 9 payments
  5. Sunovion Pharmaceuticals Inc. $114 9 payments
  6. Vanda Pharmaceuticals Inc. $84 6 payments
  7. Neurocrine Biosciences, Inc. $78 6 payments
  8. RTI Surgical, Inc. $73 1 payment
  9. Medtronic USA, Inc. $63 1 payment
  10. Providence Medical Technology, Inc. $56 1 payment
  11. Other $37 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Royalty or License $1,554 1 payment
  2. Food and Beverage $1,039 40 payments
  3. Education $111 1 payment
Products named General payments · program years 2019–2024
  1. Mesh $1,554 1 payment
  2. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $197 1 payment
  3. AUSTEDO $149 2 payments
  4. Briviact $114 7 payments
  5. APTIOM $114 9 payments
  6. FANAPT $84 6 payments
  7. HETLIOZ $84 6 payments
  8. ALLOGRAFT $73 1 payment
  9. ASCENDA $63 1 payment
  10. CAVUX Cervical Cage $56 1 payment
  11. Other $298 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

2,087

Median for Orthopedic Surgery: 203

Drug cost

$147,978

Median for Orthopedic Surgery: $1,433

Branded share of claims

13.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 15 $27,036
Eliquis Apixaban Brand 25 $16,505
Linzess Linaclotide Brand 30 $16,487
Rybelsus Semaglutide Brand 14 $14,370
Janumet Sitagliptin Phos/Metformin Hcl Brand 13 $7,716
Vascepa Icosapent Ethyl Brand 13 $6,346
Breo Ellipta Fluticasone/Vilanterol Brand 13 $5,536
Levetiracetam Generic 101 $5,336
Desmopressin Acetate Generic 34 $5,275
Divalproex Sodium Generic 29 $4,057

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$3,534

Medicare's payments for the services billed

Medicare patients

41

Average age 52

Services billed

119

18 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 39%
Depression 27%
Ischemic heart disease 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record